Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 4/20 | 0.36 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.36 |
| ▸ | CMA1 | P23946 | 6/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPM1A | P35813 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689854 | 0.92 | HTR6 (0.40) | CMA1 | |
| SCHEMBL3688486 | 0.91 | KDM4E (0.35) | CMA1PPARGPPARAPPARD | |
| SCHEMBL3686015 | 0.86 | CMA1 (0.38) | PER2CRY1CRY2CMA1PPARG | |
| SCHEMBL3684613 | 0.86 | PPARG (0.34) | PER2CRY1CRY2CMA1PPARG | |
| SCHEMBL3681651 | 0.78 | PPARD (0.42) | CMA1PPARGPPARAPPARD | |
| SCHEMBL3690427 | 0.78 | HTR6 (0.41) | CMA1 | |
| SCHEMBL3682153 | 0.77 | PPARD (0.44) | CMA1PPARGPPARAPPARD | |
| SCHEMBL3688162 | 0.77 | ALDH1A1 (0.45) | PPARGPPARA | |
| SCHEMBL3683155 | 0.76 | MCL1 (0.34) | PPARGPPARAPPARD | |
| SCHEMBL13508324 | 0.75 | PPARG (0.43) | CMA1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PER2 782/4885CRY1 1905/4885CRY2 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.